Overexpression of the pp32r1 (ANP32C) oncogene or its functional mutant pp32r1Y140H confers enhanced resistance to FTY720 (Finguimod)

References

• Matilla A, Radrizzani M. The Anp32 family of proteins containing leucine-rich repeats. Cerebellum 2005; 4:7 - 18; http://dx.doi.org/10.1080/14734220410019020; PMID: 15895553
   PubMed Web of Science ®Google Scholar
• Malek SN, Katumuluwa AI, Pasternack GR. Identification and preliminary characterization of two related proliferation-associated nuclear phosphoproteins. J Biol Chem 1990; 265:13400 - 9; PMID: 2376600
   PubMed Web of Science ®Google Scholar
• Matilla A, Koshy BT, Cummings CJ, Isobe T, Orr HT, Zoghbi HY. The cerebellar leucine-rich acidic nuclear protein interacts with ataxin-1. Nature 1997; 389:974 - 8; http://dx.doi.org/10.1038/40159; PMID: 9353121
   PubMed Web of Science ®Google Scholar
• Opal P, Garcia JJ, McCall AE, Xu B, Weeber EJ, Sweatt JD, Orr HT, Zoghbi HY. Generation and characterization of LANP/pp32 null mice. Mol Cell Biol 2004; 24:3140 - 9; http://dx.doi.org/10.1128/MCB.24.8.3140-3149.2004; PMID: 15060138
   PubMed Web of Science ®Google Scholar
• Reilly PT, Afzal S, Gorrini C, Lui K, Bukhman YV, Wakeham A, Haight J, Ling TW, Cheung CC, Elia AJ, et al. Acidic nuclear phosphoprotein 32kDa (ANP32)B-deficient mouse reveals a hierarchy of ANP32 importance in mammalian development. Proc Natl Acad Sci U S A 2011; 108:10243 - 8; http://dx.doi.org/10.1073/pnas.1106211108; PMID: 21636789
   PubMed Web of Science ®Google Scholar
• Reilly PT, Afzal S, Wakeham A, Haight J, You-Ten A, Zaugg K, Dembowy J, Young A, Mak TW. Generation and characterization of the Anp32e-deficient mouse. PLoS One 2010; 5:e13597; http://dx.doi.org/10.1371/journal.pone.0013597; PMID: 21049064
   PubMedGoogle Scholar
• Brody JR, Kadkol SS, Mahmoud MA, Rebel JM, Pasternack GR. Identification of sequences required for inhibition of oncogene-mediated transformation by pp32. J Biol Chem 1999; 274:20053 - 5; http://dx.doi.org/10.1074/jbc.274.29.20053; PMID: 10400610
   PubMed Web of Science ®Google Scholar
• Kadkol SS, Brody JR, Pevsner J, Bai J, Pasternack GR. Correction to “Modulation of oncogenic potential by alternative gene use in human prostate cancer”. Nat Med 1999; 5:1087; http://dx.doi.org/10.1038/12530; PMID: 10471270
   PubMed Web of Science ®Google Scholar
• Adegbola O, Pasternack GR. Phosphorylated retinoblastoma protein complexes with pp32 and inhibits pp32-mediated apoptosis. J Biol Chem 2005; 280:15497 - 502; http://dx.doi.org/10.1074/jbc.M411382200; PMID: 15716273
   PubMed Web of Science ®Google Scholar
• Kobe B, Kajava AV. The leucine-rich repeat as a protein recognition motif. Curr Opin Struct Biol 2001; 11:725 - 32; http://dx.doi.org/10.1016/S0959-440X(01)00266-4; PMID: 11751054
   PubMed Web of Science ®Google Scholar
• Huyton T, Wolberger C. The crystal structure of the tumor suppressor protein pp32 (Anp32a): structural insights into Anp32 family of proteins. Protein Sci 2007; 16:1308 - 15; http://dx.doi.org/10.1110/ps.072803507; PMID: 17567741
   PubMed Web of Science ®Google Scholar
• Chen TH, Brody JR, Romantsev FE, Yu JG, Kayler AE, Voneiff E, Kuhajda FP, Pasternack GR. Structure of pp32, an acidic nuclear protein which inhibits oncogene-induced formation of transformed foci. Mol Biol Cell 1996; 7:2045 - 56; http://dx.doi.org/10.1091/mbc.7.12.2045; PMID: 8970164
   PubMed Web of Science ®Google Scholar
• Brennan CM, Gallouzi IE, Steitz JA. Protein ligands to HuR modulate its interaction with target mRNAs in vivo. J Cell Biol 2000; 151:1 - 14; http://dx.doi.org/10.1083/jcb.151.1.1; PMID: 11018049
   PubMed Web of Science ®Google Scholar
• Buddaseth S, Göttmann W, Blasczyk R, Huyton T. Dysregulation of cell cycle control caused by overexpression of the oncogene pp32r1 (ANP32C) and the Tyr>His mutant pp32r1Y140H. Biochim Biophys Acta 2013; 1833:1212 - 21; http://dx.doi.org/10.1016/j.bbamcr.2013.02.001; PMID: 23403278
   PubMed Web of Science ®Google Scholar
• Kochevar GJ, Brody JR, Kadkol SS, Murphy KM, Pasternack GR. Identification of a functional mutation in pp32r1 (ANP32C). Hum Mutat 2004; 23:546 - 51; http://dx.doi.org/10.1002/humu.20030; PMID: 15146458
   PubMed Web of Science ®Google Scholar
• Habrukowich C, Han DK, Le A, Rezaul K, Pan W, Ghosh M, Li Z, Dodge-Kafka K, Jiang X, Bittman R, et al. Sphingosine interaction with acidic leucine-rich nuclear phosphoprotein-32A (ANP32A) regulates PP2A activity and cyclooxygenase (COX)-2 expression in human endothelial cells. J Biol Chem 2010; 285:26825 - 31; http://dx.doi.org/10.1074/jbc.M110.147058; PMID: 20558741
   PubMed Web of Science ®Google Scholar
• Tedesco-Silva H, Mourad G, Kahan BD, Boira JG, Weimar W, Mulgaonkar S, Nashan B, Madsen S, Charpentier B, Pellet P, et al. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 2004; 77:1826 - 33; PMID: 15223899
   PubMed Web of Science ®Google Scholar
• Kappos L, Antel J, Comi G, Montalban X, O’Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW, FTY720 D2201 Study Group. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355:1124 - 40; http://dx.doi.org/10.1056/NEJMoa052643; PMID: 16971719
   PubMed Web of Science ®Google Scholar
• Shen Y, Cai M, Xia W, Liu J, Zhang Q, Xie H, Wang C, Wang X, Zheng S. FTY720, a synthetic compound from Isaria sinclairii, inhibits proliferation and induces apoptosis in pancreatic cancer cells. Cancer Lett 2007; 254:288 - 97; http://dx.doi.org/10.1016/j.canlet.2007.03.013; PMID: 17462818
   PubMed Web of Science ®Google Scholar
• Azuma H, Takahara S, Horie S, Muto S, Otsuki Y, Katsuoka Y. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J Urol 2003; 169:2372 - 7; http://dx.doi.org/10.1097/01.ju.0000064938.32318.91; PMID: 12771800
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhao X, Frissora F, Ma Y, Santhanam R, Jarjoura D, Lehman A, Perrotti D, Chen CS, Dalton JT, et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 2008; 111:275 - 84; http://dx.doi.org/10.1182/blood-2006-10-053884; PMID: 17761520
   PubMed Web of Science ®Google Scholar
• Liao A, Broeg K, Fox T, Tan SF, Watters R, Shah MV, Zhang LQ, Li Y, Ryland L, Yang J, et al. Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia. Blood 2011; 118:2793 - 800; http://dx.doi.org/10.1182/blood-2011-01-331447; PMID: 21768294
   PubMed Web of Science ®Google Scholar
• Chua CW, Lee DT, Ling MT, Zhou C, Man K, Ho J, Chan FL, Wang X, Wong YC. FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer. Int J Cancer 2005; 117:1039 - 48; http://dx.doi.org/10.1002/ijc.21243; PMID: 15986440
   PubMed Web of Science ®Google Scholar
• Ho JW, Man K, Sun CK, Lee TK, Poon RT, Fan ST. Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. Mol Cancer Ther 2005; 4:1430 - 8; http://dx.doi.org/10.1158/1535-7163.MCT-05-0021; PMID: 16170036
   PubMed Web of Science ®Google Scholar
• Lee TK, Man K, Ho JW, Sun CK, Ng KT, Wang XH, Wong YC, Ng IO, Xu R, Fan ST. FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation. Carcinogenesis 2004; 25:2397 - 405; http://dx.doi.org/10.1093/carcin/bgh250; PMID: 15297371
   PubMed Web of Science ®Google Scholar
• Permpongkosol S, Wang JD, Takahara S, Matsumiya K, Nonomura N, Nishimura K, Tsujimura A, Kongkanand A, Okuyama A. Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis. Int J Cancer 2002; 98:167 - 72; http://dx.doi.org/10.1002/ijc.10178; PMID: 11857403
   PubMed Web of Science ®Google Scholar
• Costantino CL, Witkiewicz AK, Kuwano Y, Cozzitorto JA, Kennedy EP, Dasgupta A, Keen JC, Yeo CJ, Gorospe M, Brody JR. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res 2009; 69:4567 - 72; http://dx.doi.org/10.1158/0008-5472.CAN-09-0371; PMID: 19487279
   PubMed Web of Science ®Google Scholar
• Williams TK, Costantino CL, Bildzukewicz NA, Richards NG, Rittenhouse DW, Einstein L, Cozzitorto JA, Keen JC, Dasgupta A, Gorospe M, et al. pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs. PLoS One 2010; 5:e15455; http://dx.doi.org/10.1371/journal.pone.0015455; PMID: 21152064
   PubMedGoogle Scholar
• Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 2009; 30:2785 - 91; http://dx.doi.org/10.1002/jcc.21256; PMID: 19399780
   PubMed Web of Science ®Google Scholar
• Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 2007; 117:2408 - 21; http://dx.doi.org/10.1172/JCI31095; PMID: 17717597
   PubMed Web of Science ®Google Scholar
• Don AS, Martinez-Lamenca C, Webb WR, Proia RL, Roberts E, Rosen H. Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues. J Biol Chem 2007; 282:15833 - 42; http://dx.doi.org/10.1074/jbc.M609124200; PMID: 17400555
   PubMed Web of Science ®Google Scholar
• Wallington-Beddoe CT, Hewson J, Bradstock KF, Bendall LJ. FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells. Autophagy 2011; 7:707 - 15; http://dx.doi.org/10.4161/auto.7.7.15154; PMID: 21460633
   PubMed Web of Science ®Google Scholar
• Seo SB, Macfarlan T, McNamara P, Hong R, Mukai Y, Heo S, Chakravarti D. Regulation of histone acetylation and transcription by nuclear protein pp32, a subunit of the INHAT complex. J Biol Chem 2002; 277:14005 - 10; http://dx.doi.org/10.1074/jbc.M112455200; PMID: 11830591
   PubMed Web of Science ®Google Scholar
• Chakravarti D, Hong R. SET-ting the stage for life and death. Cell 2003; 112:589 - 91; http://dx.doi.org/10.1016/S0092-8674(03)00151-X; PMID: 12628178
   PubMed Web of Science ®Google Scholar
• Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, Bielawski J, Szulc ZM, Thomas RJ, Selvam SP, et al. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med 2013; 5:105 - 21; http://dx.doi.org/10.1002/emmm.201201283; PMID: 23180565
   PubMed Web of Science ®Google Scholar
• Li M, Damuni Z. I1PP2A and I2PP2A. Two potent protein phosphatase 2A-specific inhibitor proteins. Methods Mol Biol 1998; 93:59 - 66; PMID: 9664527
   PubMedGoogle Scholar
• Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, Hahn WC, Stukenberg PT, Shenolikar S, Uchida T, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol 2004; 6:308 - 18; http://dx.doi.org/10.1038/ncb1110; PMID: 15048125
   PubMed Web of Science ®Google Scholar
• Kadkol SS, Brody JR, Pevsner J, Bai J, Pasternack GR. Modulation of oncogenic potential by alternative gene use in human prostate cancer. Nat Med 1999; 5:275 - 9; http://dx.doi.org/10.1038/12530; PMID: 10086381
   PubMed Web of Science ®Google Scholar
• Kadkol SS, El Naga GA, Brody JR, Bai J, Gusev Y, Dooley WC, Pasternack GR. Expression of pp32 gene family members in breast cancer. Breast Cancer Res Treat 2001; 68:65 - 73; http://dx.doi.org/10.1023/A:1017919507109; PMID: 11678310
   PubMed Web of Science ®Google Scholar
• Wang JD, Takahara S, Nonomura N, Ichimaru N, Toki K, Azuma H, Matsumiya K, Okuyama A, Suzuki S. Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation. Prostate 1999; 40:50 - 5; http://dx.doi.org/10.1002/(SICI)1097-0045(19990615)40:1<50::AID-PROS6>3.0.CO;2-N; PMID: 10344723
   PubMed Web of Science ®Google Scholar
• Pchejetski D, Bohler T, Brizuela L, Sauer L, Doumerc N, Golzio M, Salunkhe V, Teissié J, Malavaud B, Waxman J, et al. FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. Cancer Res 2010; 70:8651 - 61; http://dx.doi.org/10.1158/0008-5472.CAN-10-1388; PMID: 20959468
   PubMed Web of Science ®Google Scholar